An observational study in Familial Mediterranean Fever, sponsored by Assiut University. Not yet recruiting. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This cross-sectional study aims to assess the spectrum of MEFV gene mutations and their relation to clinical manifestations and disease severity in children with Familial Mediterranean Fever attending Assiut University Children Hospital.
Familial Mediterranean Fever is a common autoinflammatory disease in children of Mediterranean origin. This observational study will include pediatric patients with a clinical diagnosis of FMF according to Tel-Hashomer or Yalcinkaya-Ozen criteria who have available MEFV genetic testing.
Clinical features, disease severity (ISSF score), and genetic variants will be recorded and analyzed in a single assessment.
61 studies on the registry are indexed under Familial Mediterranean Fever; 27 are open to participants now.
This study's planned enrollment of 84 is close to the median of 89 across 30 observational studies indexed under Familial Mediterranean Fever.
Browse Familial Mediterranean Fever studies →Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Pediatric patients with Familial Mediterranean Fever attending the Pediatric Allergy, Immunology and Rheumatology Unit at Assiut University Children Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children with confirmed clinical diagnosis of Familial Mediterranean Fever who have available MEFV genetic results and will undergo clinical and severity assessment.
Frequency of MEFV gene mutations
Proportion of children with MEFV gene mutations among the studied pediatric FMF patients.
Time frame: Baseline
Mean ISSF disease severity score
Mean International Severity Scoring System for Familial Mediterranean Fever (ISSF) score. The score ranges from 0 to 14, with higher scores indicating more severe disease.
Time frame: Baseline
Mean age at symptom onset
Mean age at symptom onset of FMF in years..
Time frame: Baseline
Mean age at diagnosis
Mean age at diagnosis of FMF in years.
Time frame: Baseline
Frequency of fever attacks
Proportion of children presenting with recurrent fever attacks.
Time frame: Baseline
Frequency of abdominal pain
Proportion of children presenting with abdominal pain during attacks.
Time frame: Baseline
Frequency of arthritis or arthralgia
Proportion of children presenting with arthritis or arthralgia during attacks.
Time frame: Baseline
Frequency of chest pain
Proportion of children presenting with chest pain during attacks
Time frame: Baseline
Mean colchicine dose
Mean daily colchicine dose in milligrams.
Time frame: Baseline
Proportion of patients with complete colchicine response
Proportion of patients showing complete response to colchicine therapy.
Time frame: Baseline
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Familial Mediterranean Fever →